BioPharm Asia, Inc (fka BFAR)

[hercules16]

Thanks for the reply. The extreme volatility from overvalued to undervalued is not neccessarily a bad thing, in that allows for the potential to generate trading gains (Congratulations for your trades last year, I also had some nice gains last year selling at $4 and $5). I think BFAR gets especially beat up as it is a long wait between 3rd quarter earnings and 4th quarter earnings and people are too impatient, and it is too illiquid to be suitable for the vast majority of institutions.

I've bought unloved issues before (e.g. - SFI 2 years ago) and the subsequent gains can be significant. (Edit KCAP probabaly would have been a better exapmple for my moniker here; Not quite as impresive as SFI but very nice returns nonetheless about 350% return in 2 years exculding dividends). No guarentees here of course. I also like CCME, TSTC, GFRE, CHBT.

Best Regards,
hercules